findmyKOL
Clinical trialNCT02595892Active, not recruitingPhase 2Interventional

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

SponsorNational Cancer Institute (NCI)Enrollment70Ovarian Serous TumorRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona, United States

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, United States

  • Uc San Diego Moores Cancer Center

    La Jolla, California, United States

  • Uc San Diego Medical Center - Hillcrest

    San Diego, California, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, United States

  • Wayne State University/karmanos Cancer Institute

    Detroit, Michigan, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, United States

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, United States

  • University of Pittsburgh Cancer Institute (upci)

    Pittsburgh, Pennsylvania, United States

  • Vanderbilt University/ingram Cancer Center

    Nashville, Tennessee, United States

  • Ut Md Anderson Cancer Center

    Houston, Texas, United States

  • University of Virginia Cancer Center

    Charlottesville, Virginia, United States

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
25 Aug 2016
Primary completion
15 Jun 2020
Completion
5 Aug 2026
Last update posted
17 Jun 2026
Registered enrollment
70
Registry id
NCT02595892

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.